Making cell-free DNA testing accessible to all healthcare providers
Categories: News
Published: 11 September 2025

Gene Solutions at TOTIO 2025 – Driving Innovation in Cancer Care

Udaipur, India – August 22–24, 2025 – Gene Solutions participated in the prestigious TOTIO 2025 Conference, where Dr. Nguyen Duy Sinh, Oncology Medical Director at Gene Solutions, presented groundbreaking clinical validation data and AI-driven circulating tumor DNA (ctDNA) technologies to over 200 oncology experts dedicated to multidisciplinary cancer care and research. 

In his presentation titled “ctDNA and HPV DNA Detection in Surveillance and Early Recurrence (Head & Neck Cancer)”, Dr. Sinh shared key insights on: 

  • The accelerating global adoption of ctDNA technologies for early cancer detection and treatment monitoring 
  • Robust clinical evidence supporting ctHPV DNA as a diagnostic and surveillance tool in Head & Neck cancer management 
  • Latest validation data from Gene Solutions demonstrating breakthrough results in multi-cancer early detection (MCED) and molecular residual disease (MRD) monitoring 

Beyond his presentation, Dr. Sinh served as session chair for ‘Serplulimab in ES-SCLC: A New Survival Benchmark,’ fostering an engaging exchange of clinical perspectives among oncologists across Asia. 

Following the successful conference participation, Gene Solutions formalized its commitment to the Indian cancer care community by signing a Memorandum of Understanding (MoU) with SunAct Cancer Institute. 

Gene Solutions’ flagship innovations—🔹 SPOT-MAS  (Multi-Cancer Early Detection) and 🔹 K-4CARE  (Comprehensive Genomic & Transcriptomic Profiling + ctDNA-MRD Monitoring)—are designed to revolutionize cancer patient care through advanced liquid biopsy solutions. 

Gene Solutions remains committed to advancing precision oncology through innovative genetic testing and liquid biopsy technologies, making early detection and personalized treatment accessible across Asia. 

Gene Solutions at TOTIO 2025 – Driving Innovation in Cancer Care We were honored to participate in the prestigious TOTIO 2025 Conference in Udaipur, India! Our Oncology Medical Director, Dr. Nguyen Duy Sinh, presented cutting-edge clinical validation data and AI-powered ctDNA technologies to 200+ oncology experts. Key highlights from Dr. Sinh’s talk: ✅ Global adoption of ctDNA for early detection & treatment monitoring ✅ ctHPV DNA as a game-changer in Head & Neck cancer surveillance ✅ Breakthrough results in MCED and MRD monitoring Beyond his presentation, Dr. Sinh chaired the session ‘Serplulimab in ES-SCLC: A New Survival Benchmark,’ fostering an engaging exchange of clinical perspectives among oncologists across Asia. We also signed an MoU with SunAct Cancer Institute, marking a major step in bringing precision oncology and world-class genomics closer to Indian patients. Our flagship solutions: 🔹 SPOT-MAS – Multi-Cancer Early Detection 🔹 K-4CARE – Comprehensive Genomic Profiling + ctDNA-MRD

Follow us on https://genesolutions.com/ and social media for updates on our latest breakthroughs. 

#GeneSolutions #LiquidBiopsy #CancerCare #TOTIO2025 #Innovation #HealthcareInnovation #APAC